[Asia Economy Reporter Lee Gwan-joo] RP Bio announced on the 17th that it has submitted a securities registration statement to the Financial Supervisory Service and is officially starting the process of listing on the KOSDAQ.
RP Bio plans to offer 1.2 million shares in this public offering. The expected offering price is between 10,000 and 13,000 KRW per share, with a total offering amount ranging from 12 billion to 15.6 billion KRW. After conducting demand forecasting on September 15-16, the general subscription will take place on the 20th-21st, followed by entry into the KOSDAQ market. The lead underwriter is Korea Investment & Securities.
RP Bio is a pharmaceutical and health functional food OEM·ODM specialized manufacturing company established in 1983 as a joint venture between the US-based RP Scherer Corp, which holds a 70% share of the global softgel capsule market, and Daewoong Pharmaceutical. It is the only company in Korea that possesses original softgel capsule core technology and original machinery.
Kim Nam-gi, CEO of RP Bio, stated, “RP Bio has continuously grown by inheriting over 85 years of accumulated softgel capsule core technology from RP Scherer, the world's largest softgel capsule specialized manufacturer. Through the company’s listing, we will focus on maximizing corporate value and competitiveness by expanding capacity through the construction of a smart new factory and increasing customer inflow by expanding premium raw materials and formulations.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
